Autolus Therapeutics plc (AUTL) stock
AUTLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/3020% below fair value
$1.09−0.05 (-4.39%)
Close on Nov 17, 2026Market cap $290.12MP/E –Yield –
Autolus Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Autolus Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$225.61M. For fiscal 2025 it was -$283.57M. The highest annual figure on record is -$9.85M in fiscal 2016.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$283.57M | – |
| FY2024 | Dec 31, 2024 | -$206.27M | – |
| FY2023 | Dec 31, 2023 | -$145.59M | – |
| FY2022 | Dec 31, 2022 | -$112.31M | – |
| FY2021 | Dec 31, 2021 | -$117.86M | – |
| FY2020 | Dec 31, 2020 | -$117.76M | – |
| FY2018 | Sep 30, 2018 | -$31.54M | – |
| FY2017 | Sep 30, 2017 | -$16.36M | – |
| FY2016 | Sep 30, 2016 | -$9.85M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | -$25.07M | – |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | -$65.32M | – |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | -$67.32M | – |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | -$67.90M | – |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | -$72.78M | – |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | -$75.57M | – |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -$37.93M | – |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | -$76.74M | – |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | -$51.08M | – |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -$40.51M | – |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | -$24.83M | – |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | -$40.19M | – |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | -$38.15M | – |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | -$42.42M | – |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | -$14.57M | – |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | -$37.34M | – |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | -$27.73M | – |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | -$39.06M | – |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | -$26.93M | – |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | -$24.03M | – |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | -$8.80M | – |
See a number that looks wrong?